Children’s Hospital Colorado Helps Set National Standards for Sickle Cell Neurocare

Viral Science News

Today, clinicians treating sickle cell disease (SCD) are getting a new playbook aimed at a problem that has long been underestimated: developmental and cognitive risk across the lifespan. In a major collaborative effort, the National Alliance of Sickle Cell Centers (NASCC) released national standards designed to help healthcare teams identify learning and decision-making difficulties earlier and respond more consistently.

SCD is increasingly recognized as a contributor to developmental delays and cognitive challenges, even for patients who have not suffered major neurological events such as stroke. The result can be lasting effects on school performance, executive functioning, and everyday independence—areas that depend heavily on timely support.

The new guidance is intended to reduce regional disparities in care quality. Because clinical practices vary widely by location and resources, some patients may receive neurodevelopmental assessments too late, while others may not be screened at all—shaping outcomes long before adulthood.

A key advance is the adoption of a tiered model of neurodevelopmental surveillance, screening, and evaluation. Rather than relying on “trigger testing” alone, the standards emphasize proactive monitoring starting in infancy and continuing across childhood and beyond.

The recommendations also define when more comprehensive evaluation is warranted. That includes considering a broader range of medical and developmental risk factors, helping clinicians distinguish between typical variation and patterns suggesting need for specialized neurocognitive assessment.

The standards further stress patient- and family-centered education, integrating resources that can translate concern into action. By improving communication and clarity for caregivers, the framework supports early connection to services such as school accommodations and therapies.

Children’s Hospital Colorado contributed to the development of these recommendations through its neurodevelopmental monitoring program and multidisciplinary SCD care model. The institution integrates transition planning into adolescence and facilitates access to specialized neurocognitive testing when needed.

Overall, the effort aligns closely with prior guidance from the American Society of Hematology, but expands operational detail for clinical implementation. The end goal: more coordinated, lifelong care that treats cognitive health as a core component of SCD management.